المؤلفون: Gordon Beattie (7212251), Lewis Au (7562414), Emine Hatipoglu (6766298), Marc Robert De Massy (7073117), Kevin Litchfield (8768190), Andrew Rowan (11387133), Desiree Schnidrig (11387136), Rachael Thompson (7570505), Fiona Byrne (7557194), Stuart Horswell (11387139), Nicos Fotiadis (11387142), Steve Hazell (11387145), David Nicol (11387148), Scott Shepherd (7562342), Annika Fendler (169443), Robert Mason (3269031), Lyra Del Rosario (11306172), Kim Edmonds (8266020), Karla Lingard (8266023), Sarah Sarker (11387153), Mary Mangwende (11387156), Eleanor Carlyle (11306169), Jan Attig (3355682), Kroopa Joshi (7783976), Imran Uddin (8229834), Pablo D. Becker (10702171), Mariana Werner Sunderland (6769256), Ayse Akarca (6766817), Ignazio Puccio (8794061), William Yang (6779321), Tom Lund (6763991), Kim Dhillon (8229768), Marcos Vasquez Duran (6779318), Ehsan Ghorani (6782504), Hang Xu (7558895), Charlotte Spencer (3747700), Jose Lopez (276001), Anna Green (3502100), Ula Mahadeva (11387159), Elaine Borg (9556817), Miriam Mitchison (11387160), David Moore (7100663), Ian Proctor (9360179), Mary Falzon (594410), Lisa Pickering (9304160), Andrew Furness (11159853), James Reading (6776954), Roberto Salgado (8458), Teresa Marafioti (7079624), Mariam Jamal-Hanjani (6775865), George Kassiotis (165467), James Larkin (11387162), Charles Swanton (6785063), Benny Chain (6785306), Sergio Quezada (6761279), Samra Turajlic (7784021)

مصطلحات موضوعية: Cancer, ADAPTeR, TCR, Clinical Trial, Renal cell carcinoma, anti-PD-1

Relation: https://figshare.com/articles/dataset/Multi-region_TCR-seq_data_on_ADAPTeR_patient_cohort/16571573

الاتاحة: https://doi.org/10.5522/04/16571573.v1